Gilead Sciences Inc
GILD.O- Latest Trade
- trading higher83.95USD
- 0.6
- 0.72%
- As of Jan 31 2023. Values delayed up to 15 minutes
- Day Range
- 83.22 - 84.21
- 52-Week Range
- 57.16 - 89.74
- Previous Close
- 83.35
- Open
- 83.52
- Volume
- 9,528,300.00
- 3 Month Average Trading Volume
- 151.94
- Shares Out (Mil)
- 1,254.24
- Market Cap
- 105,017.80
- Forward P/E
- 11.73
- Dividend Yield
- 3.49
Key Statistics
2.5483871 mean rating - 31 analysts
- P/E Excl. Extra Items (TTM)
- 31.66
- Price To Sales (TTM)
- 3.87
- Price To Book (Quarterly)
- 4.98
- Price To Cash Flow (Per Share TTM)
- 19.38
- Total Debt/Total Equity (Quarterly)
- 119.65
- Long Term Debt/Equity (Quarterly)
- 108.88
- Return On Investment (TTM)
- 6.07
- Return On Equity (TTM)
- 5.10
2021 (millions USD)
About Gilead Sciences Inc (GILD.O)
Company Information
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. Its COVID-19 product is Veklury. The products for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
Address
333 LAKESIDE DRFOSTER CITY, CA
94404
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Daniel O'Day
- Chairman of the Board, Chief Executive Officer
- Andrew D. Dickinson
- Chief Financial Officer
- Deborah H. Telman
- Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary
- Stacey Ma
- Executive Vice President - Pharmaceutical Development and Manufacturing
- Flavius Martin
- Executive Vice President - Research
- Johanna Mercier
- Chief Commercial Officer
- Merdad V. Parsey
- Chief Medical Officer
- Kevin E. Lofton
- Lead Independent Director
- Jacqueline K. Barton
- Independent Director
- Jeffrey A. Bluestone
- Independent Director
- Sandra J. Horning
- Independent Director
- Kelly A. Kramer
- Independent Director
- Harish Manwani
- Independent Director
- Javier J. Rodriguez
- Independent Director
- Anthony Welters
- Independent Director
Latest News
Markets Performance
Official Data PartnerCommodities
Future | Last | % Change |
---|---|---|
Gold | 1,927.50 | 0.24% |
Copper | 772.90 | 1.09% |
Brent Crude Oil | 84.47 | 0.51% |
CBOT Soybeans | 1,538.00 | 0.18% |
Stocks
Index | Last | % Change |
---|---|---|
S&P 500 | 4,076.60 | 1.46% |
Euro STOXX 50 | 4,163.45 | 0.12% |
FTSE 100 | 7,771.70 | 0.17% |
Nikkei 225 | 27,327.11 | 0.39% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes